| |
Age < 70 years (N = 333) n (%)
|
Age ≥ 70 years (N = 188) n (%)
|
All patients (N = 521) n (%)
|
|---|
|
Histology
| | | |
|---|
|
Non-squamous cell carcinoma
|
283 (85.0)
|
161 (85.6)
|
444 (85.2)
|
|
Squamous cell carcinomaa
|
50 (15.0)
|
27 (14.4)
|
77 (14.8)
|
|
Disease stage at study entry
| | | |
|
Stage IIIa
|
18 ( 5.4)
|
17 ( 9.0)
|
35 ( 6.7)
|
|
Stage IIIb
|
65 (19.5)
|
38 (20.2)
|
103 (19.8)
|
|
Stage IV
|
250 (74.1)
|
133 (70.7)
|
383 (73.5)
|
|
Karnofsky Index (KI)
| | | |
|
KI ≥ 80%
|
207 (62.2)
|
116 (61.7)
|
323 (62.0)
|
|
KI 70%
|
89 (26.7)
|
45 (23.9)
|
134 (25.7)
|
|
KI 60%
|
27 ( 8.1)
|
18 ( 9.6)
|
45 ( 8.6)
|
|
KI 50%
|
10 ( 3.0)
|
8 ( 4.3)
|
18 ( 3.5)
|
|
Missing data
|
0 ( 0.0)
|
1 ( 0.5)
|
1 ( 0.2)
|
- N = total number of patients, n = number of patients
-
a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
